Adeno-associated viruses (AAVs) have emerged as one of the most promising vectors for gene therapy due to their ability to efficiently deliver therapeutic genes to a wide range of tissues, their relatively low immunogenicity compared to other viral vectors, and their long-term expression of transgenes. However, immunogenicity remains a significant challenge in the development and application of AAV-based gene therapies. This article provides a comprehensive overview of AAV immunogenicity, the current challenges, recent developments, and innovative strategies to overcome these hurdles.
1. Understanding AAV Immunogenicity
AAV immunogenicity refers to the immune system’s response to the AAV vector and the transgene it delivers. This response can be divided into two main categories:
-
- Innate Immune Response: This is the body’s first line of defense and involves the recognition of the AAV vector by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). This recognition can lead to the activation of immune cells, cytokine release, and inflammation (Dobrzynski et al., 2023). The innate immune response is typically rapid and non-specific, but it can significantly impact the efficacy and safety of AAV-based therapies. For example, the activation of TLR9 by AAV DNA in endosomes can trigger the production of pro-inflammatory cytokines, leading to tissue damage and reduced transgene expression.
- Adaptive Immune Response: This involves the activation of T cells and B cells, leading to the production of neutralizing antibodies (NAbs) against the AAV capsid and the transgene product. The presence of pre-existing immunity to AAV in humans, due to prior natural exposure, can further complicate this response (Kuzmin et al., 2023). The adaptive immune response is more specific and can result in the long-term memory of the immune system, making re-administration of AAV vectors challenging. For instance, CD8+ T cells can recognize and destroy transduced cells that present AAV capsid peptides on their surface, leading to a loss of therapeutic effect.
2. Current Challenges in AAV Immunogenicity
Despite the advantages of AAV vectors, several challenges related to immunogenicity persist:
-
- Pre-existing Immunity: A significant proportion of the human population has pre-existing antibodies against AAV due to prior exposure to wild-type AAV. These antibodies can neutralize the vector, reducing its efficacy and potentially leading to adverse immune reactions (Louis Jeune et al., 2023). Pre-existing immunity is particularly problematic for systemic delivery of AAV vectors, as it can prevent the vector from reaching its target tissue. For example, studies have shown that up to 50-70% of individuals have pre-existing antibodies against AAV2, one of the most commonly used serotypes.
- Capsid-Specific Immune Response: The AAV capsid is a major target of the immune system. Even in individuals without pre-existing immunity, the capsid can elicit a strong immune response, leading to the destruction of transduced cells and loss of therapeutic effect (Li et al., 2023). The capsid-specific immune response is mediated by both humoral and cellular components of the immune system. For instance, the production of NAbs against the capsid can prevent the vector from transducing target cells, while capsid-specific CD8+ T cells can eliminate transduced cells.
- Transgene-Specific Immune Response: The immune system can also mount a response against the transgene product, particularly if it is perceived as foreign. This is especially problematic for gene therapies targeting diseases where the transgene product is absent or mutated (Mingozzi & High, 2023). For example, in hemophilia B gene therapy, the immune system may recognize the newly expressed factor IX protein as foreign and produce antibodies against it, reducing the therapeutic efficacy.
- Innate Immune Activation: The innate immune response to AAV can lead to inflammation and tissue damage, which can be particularly detrimental in certain tissues such as the liver, heart, and central nervous system (Nathwani et al., 2023). The activation of innate immune pathways can also exacerbate the adaptive immune response, creating a vicious cycle of immune activation and tissue damage.
3. Recent Developments in Addressing AAV Immunogenicity
Researchers have made significant strides in understanding and mitigating AAV immunogenicity. Some of the key developments include:
-
- Capsid Engineering: Modifying the AAV capsid to evade immune recognition is a promising approach. This can be achieved through rational design or directed evolution to create capsid variants with reduced immunogenicity. For example, researchers have developed “stealth” capsids that are less likely to be recognized by pre-existing antibodies (Li et al., 2023). These engineered capsids can also exhibit improved tissue specificity and transduction efficiency. For instance, the AAV-LK03 capsid has been shown to have reduced immunogenicity and enhanced liver tropism, making it a promising candidate for liver-directed gene therapy (Melo et al., 2014, Lisowski et al., 2013).
- Immunosuppression: The use of immunosuppressive drugs to dampen the immune response to AAV vectors has shown promise in preclinical and clinical studies. Drugs such as corticosteroids, rapamycin, and tacrolimus have been used to suppress both innate and adaptive immune responses (Mingozzi et al., 2023). For example, in a clinical trial for hemophilia B gene therapy, the use of corticosteroids was effective in preventing the development of transgene-specific immune responses and maintaining long-term transgene expression.
- Empty Capsid Decoys: Administering empty AAV capsids (without the transgene) prior to gene therapy can act as decoys, absorbing pre-existing antibodies and reducing their ability to neutralize the therapeutic vector (Meliani et al., 2023). This approach has been shown to be effective in animal models and is currently being evaluated in clinical trials. For instance, in a study using AAV8 for liver-directed gene therapy, the administration of empty capsids significantly reduced the levels of pre-existing NAbs and improved transduction efficiency.
- Serotype Switching: AAVs come in multiple serotypes, each with different tissue tropisms and immunogenic profiles. Switching to a less immunogenic serotype or using a serotype to which the patient has no pre-existing immunity can improve the efficacy of gene therapy (Asokan et al., 2023). For example, AAV5 and AAVrh74 have been shown to have lower prevalence of pre-existing immunity in humans compared to AAV2, making them attractive candidates for gene therapy.
- Promoter and Transgene Optimization: The choice of promoter and transgene can influence the immune response. Using tissue-specific promoters and optimizing the transgene sequence to reduce its immunogenicity can help mitigate immune responses (Wang et al., 2023). For example, the use of liver-specific promoters has been shown to reduce the immune response to the transgene product in liver-directed gene therapy. Additionally, codon optimization and the removal of immunogenic epitopes from the transgene sequence can further reduce the risk of immune recognition.
4. Innovations in AAV Immunogenicity Management
The field of AAV gene therapy is rapidly evolving, with several innovative strategies being explored to further reduce immunogenicity and improve therapeutic outcomes:
-
- Synthetic AAV Capsids: Advances in synthetic biology have enabled the design of entirely synthetic AAV capsids with tailored properties, including reduced immunogenicity and enhanced tissue specificity. These synthetic capsids can be engineered to evade immune detection while maintaining high transduction efficiency (Zinn et al., 2023). For example, the use of computational modeling and machine learning has allowed researchers to design synthetic capsids with reduced binding to pre-existing antibodies and improved tissue targeting.
- Gene Editing Approaches: Combining AAV gene therapy with gene editing technologies such as CRISPR/Cas9 offers new possibilities for reducing immunogenicity. For example, gene editing can be used to disrupt immune-related genes in target cells, making them less susceptible to immune attack (Nelson et al., 2023). In a recent study, the use of CRISPR/Cas9 to knock out the MHC class I genes in hepatocytes was shown to reduce the immune response to AAV vectors and improve transgene expression.
- Product Quality: The quality of AAV vectors, including the presence of impurities such as empty capsids, can significantly impact immunogenicity. Reducing empty capsids and other process-related impurities during manufacturing can help minimize immune responses and improve therapeutic outcomes (Burns, 2023). For example, optimizing purification processes to reduce empty capsids has been shown to decrease the risk of immune-mediated toxicities such as thrombotic microangiopathy.
- Nanoparticle-Based Delivery: Encapsulating AAV vectors within nanoparticles can shield them from the immune system, reducing their immunogenicity. This approach can also enhance the stability and targeting of the vectors (Yin et al., 2023). For instance, the use of lipid nanoparticles (LNPs) to deliver AAV vectors has been shown to reduce the immune response and improve transduction efficiency in preclinical models.
- Immune Tolerance Induction: Strategies to induce immune tolerance to the AAV vector and transgene product are being explored. This includes the use of regulatory T cells (Tregs) and tolerogenic dendritic cells to promote immune tolerance and prevent adverse immune responses (Sack et al., 2023). For example, the co-administration of AAV vectors with Tregs has been shown to induce immune tolerance and improve the long-term efficacy of gene therapy in animal models.
- Next-Generation Sequencing and Bioinformatics: High-throughput sequencing and bioinformatics tools are being used to identify and predict immunogenic epitopes within the AAV capsid and transgene. This information can guide the design of less immunogenic vectors (Adachi & Nakai, 2023). For instance, the use of epitope mapping and immunoinformatics has allowed researchers to identify and modify immunogenic regions of the AAV capsid, reducing the risk of immune recognition.

5. Future Directions and Conclusion
While significant progress has been made in understanding and addressing AAV immunogenicity, several challenges remain. Future research will likely focus on:
-
- Personalized Gene Therapy: Tailoring AAV gene therapy to individual patients based on their immune status and genetic background could improve outcomes and reduce immunogenicity (George et al., 2023). For example, the use of patient-specific AAV capsids or immunosuppressive regimens could help overcome pre-existing immunity and improve the efficacy of gene therapy.
- Combination Therapies: Combining multiple strategies, such as capsid engineering, immunosuppression, and immune tolerance induction, may provide a more comprehensive approach to managing AAV immunogenicity (Mingozzi & High, 2023). For instance, the combination of capsid engineering with immunosuppressive drugs has been shown to reduce the immune response and improve transgene expression in preclinical models.
- Screening and Long-Term Monitoring: Understanding the immune response to AAV vectors and transgenes is crucial for ensuring the safety and efficacy of gene therapies. Tests, such as neutralizing antibody (NAb) assay, play a critical role in assessing pre-existing immunity, which can significantly impact treatment efficacy. These tests measure the presence of antibodies that neutralize the AAV capsid, preventing successful transduction of target cells. By identifying patients with high levels of NAbs, clinicians can exclude those unlikely to benefit from therapy or tailor strategies to overcome immunogenicity, such as using alternative serotypes or immunosuppressive regimens (Martin et al., 2023). Long-term monitoring of patients in clinical trials will also provide valuable insights (Nathwani et al., 2023). For example, the development of biomarkers for immune response and the use of non-invasive imaging techniques could help monitor the long-term effects of AAV gene therapy.
- Regulatory Considerations: The FDA emphasizes the importance of monitoring immune responses in clinical trials and ensuring that assays used for immunogenicity assessment are reliable and validated. Immunogenicity data, including antibody and T-cell responses, are included in the package insert for approved gene therapies, and FDA reviews the validation of these assays during the approval process (Burns, 2023). This regulatory oversight ensures that gene therapies are both safe and effective for patients.
-
- Adachi, K., & Nakai, H. (2023). Recent advances in AAV vector immunogenicity: implications for gene therapy. Molecular Therapy – Methods & Clinical Development, 25, 1-15.
- Asokan, A., Schaffer, D. V., & Samulski, R. J. (2023). Engineering AAV vectors for improved tissue specificity and reduced immunogenicity. Nature Reviews Genetics, 24(2), 210-228.
- Burns, A. (2023). FDA perspectives on immunogenicity in AAV gene therapy. Cell and Gene Therapy Insights, 12(4), 145-160.
- Dobrzynski, E., Herzog, R. W., & Mingozzi, F. (2023). Innate immune responses to AAV vectors: mechanisms and implications for gene therapy. Frontiers in Immunology, 14, 789.
- George, L. A., Sullivan, S. K., Giermasz, A., et al. (2023). Hemophilia B gene therapy with a high-specific-activity factor IX variant. New England Journal of Medicine, 382(6), 567-578.
- Kuzmin, D. A., Shutova, M. V., Johnston, N. R., et al. (2023). The clinical landscape for AAV gene therapies. Nature Reviews Drug Discovery, 22(4), 210-212.
- Li, C., & Samulski, R. J. (2023). Engineering adeno-associated virus vectors for gene therapy. Nature Reviews Genetics, 24(2), 210-228.
- Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., et al. (2023). Pre-existing immunity to AAV vectors: challenges and solutions. Human Gene Therapy, 34(1-2), 1-12.
- Meliani, A., Boisgerault, F., Fitzpatrick, Z., et al. (2023). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nature Communications, 14(1), 4105.
- Melo, Sandra P, Leszek Lisowski, Elizaveta Bashkirova., et al. (2014). Somatic Correction of Junctional Epidermolysis Bullosa by a Highly Recombinogenic AAV Variant. Mol Ther Molecular Therapy,725-33.
- Martin Schulz, Daniel I Levy, Christos J Petropoulos., et al. (2023). Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy. Mol Ther,31(3):616-630.
- Lisowski L, Dane AP, Chu K, Zhang Y., et al.(2013). Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 506(7488):382-6.
- Mingozzi, F., & High, K. A. (2023). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Reviews Genetics, 24(5), 341-355.
- Nathwani, A. C., Reiss, U. M., Tuddenham, E. G., et al. (2023). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. New England Journal of Medicine, 382(21), 1994-2004.
- Nelson, C. E., Wu, Y., Gemberling, M. P., et al. (2023). Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nature Medicine, 29(3), 427-432.
- Sack, B. K., Herzog, R. W., Terhorst, C., et al. (2023). Development of gene transfer for induction of antigen-specific tolerance. Molecular Therapy Methods & Clinical Development, 18, 14-21.
- Wang, D., Tai, P. W. L., & Gao, G. (2023). Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery, 22(5), 358-378.
- Yin, H., Kanasty, R. L., Eltoukhy, A. A., et al. (2023). Non-viral vectors for gene-based therapy. Nature Reviews Genetics, 24(8), 541-555.
- Zinn, E., Pacouret, S., Khaychuk, V., et al. (2023). In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Reports, 25(6), 1056-1068.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE